NYMXF

Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. It has also developed the AlzheimAlert test. The Company operates in Canada, the United States and Switzerland.